Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...

With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.

The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

Mike Doustdar indicated potential advantages to a direct NYSE listing, citing a long-term migration of the shareholder base beyond Scandinavia and increasingly U.S.-centric investor engagement.

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...

FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.